Etrinabdione
Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity[1][2].
Product Specifications
CAS Number
1818428-24-8
Product Name Alternative
EHP-101; VCE-004.8
UNSPSC
12352005
Target
Cannabinoid Receptor; HIF/HIF Prolyl-Hydroxylase; PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling; Vitamin D Related/Nuclear Receptor
Applications
COVID-19-anti-virus
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/etrinabdione.html
Purity
99.16
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1C(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(C(NCC3=CC=CC=C3)=C1CCCCC)=O
Molecular Formula
C28H35NO3
Molecular Weight
433.58
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CB2; PPARγ
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD50 / ICAM3 (CG106), CF640R conjugate, 0.1mg/mL
CD45RO (190-2F2.5), CF405S conjugate, 0.1mg/mL
PAX8 (Renal Cell Marker) (PAX8/1492), CF647 conjugate, 0.1mg/mL
